EER | ENST | ENSG | GeneName | Region | Repeat | dsRNA structure | chr2:55524310-55525937:+ | ENST00000339012.6 | ENSG00000163001.10 | CFAP36 | intronic | AluSp,MIR,AluSq2,AluJo,(T)n,AluJr | chr2:55524310-55525937:+.alignment |
chr2:55524310-55525937:+ | ENST00000349456.7 | ENSG00000163001.10 | CFAP36 | intronic | AluSp,MIR,AluSq2,AluJo,(T)n,AluJr | chr2:55524310-55525937:+.alignment |
chr2:55524310-55525937:+ | ENST00000403007.4 | ENSG00000163001.10 | CFAP36 | intronic | AluSp,MIR,AluSq2,AluJo,(T)n,AluJr | chr2:55524310-55525937:+.alignment |
chr2:55524310-55525937:+ | ENST00000406691.6 | ENSG00000163001.10 | CFAP36 | intronic | AluSp,MIR,AluSq2,AluJo,(T)n,AluJr | chr2:55524310-55525937:+.alignment |
chr2:55524310-55525937:+ | ENST00000407816.6 | ENSG00000163001.10 | CFAP36 | intronic | AluSp,MIR,AluSq2,AluJo,(T)n,AluJr | chr2:55524310-55525937:+.alignment |
chr2:55536825-55537365:+ | ENST00000490934.1 | ENSG00000163001.10 | CFAP36 | ncRNA_intronic | AluSz6,AluSx1 | chr2:55536825-55537365:+.alignment |
chr2:55538525-55538744:+ | ENST00000490934.1 | ENSG00000163001.10 | CFAP36 | ncRNA_intronic | AluJr,AluSp | chr2:55538525-55538744:+.alignment |
chr2:55540712-55541358:+ | ENST00000490934.1 | ENSG00000163001.10 | CFAP36 | ncRNA_intronic | L1MC1,AluJb,AluSq2 | chr2:55540712-55541358:+.alignment |
ID_events | cancer | TypeID | ImmuneCell | P | R | CorrelationPlot |
chr2:55540712-55541358:+ | BRCA | EER | T_cells_CD4_memory_activated | 1.0938e-02 | 0.4310 |  |
ENSG00000163001.10,CFAP36 | BRCA | EAG | T_cells_CD8 | 3.2517e-02 | -0.2335 |  |
ENSG00000163001.10,CFAP36 | GBM | EAG | Mast_cells_resting | 3.7855e-02 | 0.2452 |  |
chr2:55536825-55537365:+ | KIRC | EER | Dendritic_cells_activated | 3.8576e-03 | 0.4364 |  |
ENSG00000163001.10,CFAP36 | KIRC | EAG | T_cells_regulatory_(Tregs) | 1.2906e-02 | 0.2687 | .ENSG00000163001.10,CFAP36.png) |
ENSG00000163001.10,CFAP36 | KIRP | EAG | T_cells_gamma_delta | 2.6642e-02 | 0.3504 |  |
chr2:55540712-55541358:+ | LGG | EER | NK_cells_resting | 7.0327e-03 | -0.1605 |  |
ENSG00000163001.10,CFAP36 | LUAD | EAG | T_cells_follicular_helper | 2.8263e-02 | 0.3386 |  |
ENSG00000163001.10,CFAP36 | LUSC | EAG | T_cells_follicular_helper | 1.6723e-02 | 0.5042 |  |
chr2:55524310-55525937:+ | OV | EER | Dendritic_cells_resting | 2.0244e-02 | 0.4807 |  |
chr2:55536825-55537365:+ | OV | EER | T_cells_CD4_memory_resting | 3.1154e-02 | 0.4080 |  |
chr2:55540712-55541358:+ | OV | EER | Macrophages_M0 | 1.2019e-03 | -0.3742 |  |
ENSG00000163001.10,CFAP36 | OV | EAG | Dendritic_cells_resting | 9.7976e-03 | 0.2510 |  |
chr2:55540712-55541358:+ | PCPG | EER | NK_cells_resting | 3.1009e-03 | 0.3535 |  |
ENSG00000163001.10,CFAP36 | PCPG | EAG | NK_cells_resting | 1.4033e-03 | 0.3695 |  |
ENSG00000163001.10,CFAP36 | PRAD | EAG | T_cells_follicular_helper | 8.4725e-03 | 0.4266 |  |
chr2:55536825-55537365:+ | STAD | EER | Dendritic_cells_resting | 3.4606e-05 | 0.7193 |  |
ENSG00000163001.10,CFAP36 | STAD | EAG | Dendritic_cells_resting | 1.1149e-02 | 0.3153 |  |
ENSG00000163001.10,CFAP36 | UCEC | EAG | T_cells_CD8 | 2.6780e-02 | 0.4424 |  |
ID_events | cancer | HallmarkType | Type | P | R | CorrelationPlot |
ENSG00000163001.10,CFAP36 | BRCA | GSVA_HALLMARK_ANDROGEN_RESPONSE | EAG | 4.1599e-03 | 0.3096 |  |
chr2:55540712-55541358:+ | BRCA | GSVA_HALLMARK_BILE_ACID_METABOLISM | EER | 2.7192e-02 | -0.3787 |  |
ENSG00000163001.10,CFAP36 | GBM | GSVA_HALLMARK_SPERMATOGENESIS | EAG | 3.5303e-02 | -0.2485 |  |
chr2:55540712-55541358:+ | GBM | GSVA_HALLMARK_COMPLEMENT | EER | 6.4908e-03 | 0.3343 |  |
ENSG00000163001.10,CFAP36 | KIRC | GSVA_HALLMARK_MYOGENESIS | EAG | 4.1977e-02 | 0.2211 |  |
chr2:55540712-55541358:+ | KIRC | GSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY | EER | 2.4142e-02 | 0.4410 |  |
ENSG00000163001.10,CFAP36 | KIRP | GSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY | EAG | 1.7842e-03 | 0.4786 |  |
chr2:55540712-55541358:+ | LGG | GSVA_HALLMARK_COAGULATION | EER | 1.5799e-02 | 0.1439 |  |
ENSG00000163001.10,CFAP36 | LGG | GSVA_HALLMARK_ANGIOGENESIS | EAG | 3.5816e-02 | 0.1202 |  |
ENSG00000163001.10,CFAP36 | LUAD | GSVA_HALLMARK_ESTROGEN_RESPONSE_LATE | EAG | 2.4538e-03 | 0.4552 |  |
ENSG00000163001.10,CFAP36 | OV | GSVA_HALLMARK_ALLOGRAFT_REJECTION | EAG | 2.0648e-03 | 0.2974 |  |
chr2:55536825-55537365:+ | OV | GSVA_HALLMARK_ESTROGEN_RESPONSE_LATE | EER | 1.5556e-02 | 0.4527 |  |
chr2:55540712-55541358:+ | OV | GSVA_HALLMARK_ALLOGRAFT_REJECTION | EER | 6.3335e-04 | 0.3932 |  |
chr2:55524310-55525937:+ | OV | GSVA_HALLMARK_CHOLESTEROL_HOMEOSTASIS | EER | 6.3840e-03 | 0.5514 |  |
ENSG00000163001.10,CFAP36 | PRAD | GSVA_HALLMARK_ANGIOGENESIS | EAG | 4.8495e-02 | -0.3266 |  |
chr2:55536825-55537365:+ | STAD | GSVA_HALLMARK_FATTY_ACID_METABOLISM | EER | 4.9770e-02 | 0.3886 |  |
ENSG00000163001.10,CFAP36 | THCA | GSVA_HALLMARK_MITOTIC_SPINDLE | EAG | 4.4091e-02 | -0.1574 |  |
chr2:55540712-55541358:+ | THCA | GSVA_HALLMARK_PANCREAS_BETA_CELLS | EER | 4.5374e-02 | 0.1793 |  |
ENSG00000163001.10,CFAP36 | UCEC | GSVA_HALLMARK_ALLOGRAFT_REJECTION | EAG | 2.9151e-02 | 0.4365 |  |
ID_events | cancer | Drug | Type | P | R | CorrelationPlot |
ENSG00000163001.10,CFAP36 | BRCA | EHT.1864 | EAG | 1.1992e-03 | 0.3475 |  |
chr2:55540712-55541358:+ | BRCA | Bosutinib | EER | 1.6014e-02 | 0.4101 |  |
ENSG00000163001.10,CFAP36 | ESCA | GW.441756 | EAG | 2.5612e-02 | 0.3220 |  |
ENSG00000163001.10,CFAP36 | GBM | GW843682X | EAG | 4.9320e-02 | -0.2326 |  |
chr2:55540712-55541358:+ | GBM | AICAR | EER | 1.6124e-03 | -0.3835 |  |
ENSG00000163001.10,CFAP36 | KIRC | Cyclopamine | EAG | 8.3418e-03 | -0.2844 |  |
chr2:55536825-55537365:+ | KIRC | Doxorubicin | EER | 8.8441e-03 | 0.3991 |  |
chr2:55540712-55541358:+ | KIRC | CI.1040 | EER | 1.4077e-02 | -0.4755 |  |
ENSG00000163001.10,CFAP36 | KIRP | BAY.61.3606 | EAG | 8.8739e-07 | 0.6889 |  |
chr2:55540712-55541358:+ | LGG | KU.55933 | EER | 3.4969e-03 | -0.1737 |  |
ENSG00000163001.10,CFAP36 | LGG | CHIR.99021 | EAG | 2.2943e-03 | -0.1740 |  |
ENSG00000163001.10,CFAP36 | LUAD | KIN001.135 | EAG | 6.3609e-03 | -0.4144 |  |
ENSG00000163001.10,CFAP36 | OV | CI.1040 | EAG | 6.5258e-05 | -0.3795 |  |
chr2:55536825-55537365:+ | OV | LFM.A13 | EER | 6.7441e-03 | 0.5000 |  |
chr2:55540712-55541358:+ | OV | AZD6244 | EER | 1.5045e-04 | -0.4321 |  |
chr2:55524310-55525937:+ | OV | GNF.2 | EER | 3.0445e-02 | -0.4518 |  |
chr2:55540712-55541358:+ | PCPG | Imatinib | EER | 3.9890e-03 | -0.3448 |  |
ENSG00000163001.10,CFAP36 | PCPG | Imatinib | EAG | 4.7812e-03 | -0.3290 |  |
ENSG00000163001.10,CFAP36 | PRAD | FTI.277 | EAG | 4.1225e-03 | 0.4606 |  |
ENSG00000163001.10,CFAP36 | STAD | BX.795 | EAG | 2.1468e-02 | 0.2870 |  |
chr2:55536825-55537365:+ | STAD | ATRA | EER | 1.6513e-02 | 0.4656 |  |
ENSG00000163001.10,CFAP36 | TGCT | BMS.509744 | EAG | 4.5259e-02 | -0.4412 |  |
ENSG00000163001.10,CFAP36 | THCA | AICAR | EAG | 1.8209e-05 | 0.3279 |  |
chr2:55540712-55541358:+ | THCA | CCT007093 | EER | 1.0238e-04 | 0.3404 |  |
ENSG00000163001.10,CFAP36 | UCEC | AZD7762 | EAG | 6.3441e-05 | -0.7130 |  |